NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Impact of HIV-1 viral subtype on disease progression.

Easterbrook PJ, Smith M, Geretti AM, Osner N, Murad S, Oshea S, Chrystie I, Mullen J, de Ruiter AM, Zuckerman M, HIV Virology Collaborative group GK; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. ThPpC2144.

GKT School of Medicine, London, United Kingdom

BACKGROUND: To compare the rate of disease progression prior to antiretroviral therapy (ART) and the initial response to ART in patients infected with B versus non-B HIV-1 subtypes in an ethnically diverse population of HIV infected patients in South London. METHODS: 900 HIV-1 infected patients from Kings and St. Thomas hospital HIV clinics have been subtyped using an in-house EIA assay. 306 (34%) were infected with a non-B subtype, of which subtypes A and C were the most common. Env gene sequencing is ongoing to confirm the precise distribution of subtypes A, C, and D and various mosaic strains. Rate of disease progression was determined using rate of CD4 cell decline (initial 2 years after diagnosis) stratified according to initial CD4 count (?100, 101-200, 201-400 >400 cells), and pre-treatment viral load profile; response to ART was assessed on time to a viral load ?400 copies/ml. RESULTS: Preliminary analyses were based on 457 patients with complete data. 157 were non-B and 204 were B subtype; 40 were of mixed reactivity and 56 were non-reactive. The majority of non-B subtype found in black African from sub-Saharan Africa (most commonly Uganda, Zimbabwe, Nigeria, Ivory Coast, and Ghana). B subtype patients were mainly Caucasian. 56% of non-B vs. 17% of B subtypes were female. The initial rate of CD4 decline was similar for B and non-B subtypes for each baseline CD4 cell strata. However, after initiation of ART, the % with a VL ?400 copies/ml was higher among B (51.8%) vs. non-B (35.7%) subtype patients, p=0.045. CONCLUSIONS: Based on this preliminary analysis, we found no evidence for B vs. non-B subtype specific differences in disease progression, but non-B subtype patients had a lower initial virological response to antiretroviral therapy.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Africa South of the Sahara
  • African Continental Ancestry Group
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes
  • Cote d'Ivoire
  • Disease Progression
  • European Continental Ancestry Group
  • Female
  • Genes, env
  • Ghana
  • HIV Infections
  • HIV Seropositivity
  • HIV-1
  • Humans
  • Immunoenzyme Techniques
  • London
  • Nigeria
  • Uganda
  • Viral Load
  • Zimbabwe
  • genetics
  • virology
Other ID:
  • GWAIDS0019344
UI: 102256842

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov